Skip to content

Homeopathic medicine and covid-19 pandemic: a prospective cohort study in Rio de Janeiro

Use of homeopathic therapy during the covid-19 pandemic in health units in Rio de Janeiro

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
REBEC
Registry ID
RBR-5vzynf3
Enrollment
Unknown
Registered
2023-03-29
Start date
2020-05-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

A trial longitudinal, cohort study was conducted in two groups with or without COVID-19 influenza-like symptoms that received the homeopathic medicine. Total of 51 families (128 participants) used thr
HP4.018.189.437

Sponsors

Faculdade de Farmácia da Universidade Federal do Rio de Janeiro
Lead Sponsor
Faculdade de Farmácia da Universidade Federal Fluminense
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Women and men aged 18 years or older with or not COVID-19 influenza-like symptoms were included in this study

Exclusion criteria

Exclusion criteria: The exclusion criterion was a severe acute respiratory syndrome that leads to hospitalization by primary care teams

Design outcomes

Primary

MeasureTime frame
Outcome expected 1: It is expected to find a decrease in the number or absence of symptoms similar to that of coivd-19 in the period of two months, verified using the McNemar method, based on the finding of a significance level of at least 95% confidence.;Outcome found 1: No statistically significant difference related to the severity of illness in the previous sick and health groups.

Secondary

MeasureTime frame
Outcome expected 2: It is expected to find a decrease in the number or absence of visits to emergency services, number of hospitalizations and presence of adverse events in the period of two months, analyzed by the t-student c test, based on the verification of a significance level of at least least 95% confidence. ;Outcome found 2: The secondary outcome showed that a high percentage of the participants (98.03%) reported having had general health symptoms' improvements (84.31%) and none reported adverse events.

Countries

Brazil

Contacts

Public ContactAdriana Oliveira

Faculdade de Farmácia da Universidade Federal do Rio de Janeiro

adrianapassos@pharma.ufrj.br552139386621

Outcome results

None listed

Source: REBEC (via WHO ICTRP)